Items where authors include "John, N"
Up a levelArticle
Abani, O, Abbas, A, Abbas, F et al. (6300 more authors) (2022) Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 399 (10325). pp. 665-676. ISSN 0140-6736
Ahmed, WUR, Bhatia, S, McLean, KA et al. (4545 more authors) (2022) Validation of the OAKS prognostic model for acute kidney injury after gastrointestinal surgery. BJS Open, 6 (1). zrab150. ISSN 2474-9842
Abani, O, Abbas, A, Abbas, F et al. (4809 more authors) (2021) Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet, 397 (10289). pp. 2049-2059. ISSN 0140-6736
Abani, O orcid.org/0000-0003-2209-9956, Abbas, A, Abbas, F et al. (6346 more authors) (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 397 (10285). pp. 1637-1645. ISSN 0140-6736
De Angelis, F, Connick, P, Parker, RA et al. (25 more authors) (2020) Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. Efficacy and Mechanism Evaluation, 7 (3). ISSN 2050-4365
Chataway, J, De Angelis, F, Connick, P et al. (65 more authors) (2020) Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. The Lancet Neurology, 19 (3). pp. 214-225. ISSN 1474-4422
Connick, P, De Angelis, F, Parker, RA et al. (21 more authors) (2018) Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. BMJ Open, 8 (8). 021944. ISSN 2044-6055
Proceedings Paper
Doshi, A, De Angelis, F, Muhlert, N et al. (21 more authors) (2018) Multiple Sclerosis Impact Scale and brain volume are independent predictors of cognitive impairment in Secondary Progressive Multiple Sclerosis. In: European Journal of Neurology. 4th Congress of the European Academy of Neurology, 16-19 Jul 2018, Lisbon, Portugal. Wiley , pp. 69-70.